



## Treatments for Relapsing Forms of Multiple Sclerosis

Revised Questions for Deliberation and Voting: January 20, 2023 Public Meeting

*These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.*

**Patient Population for all Questions:** Adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary-progressive multiple sclerosis.

### Clinical Evidence

1. Given the currently available evidence, is the evidence adequate to distinguish the net health benefit provided by ublituximab from that provided by other monoclonal antibodies (natalizumab [Tysabri®], ofatumumab [Kesimpta®], ocrelizumab [Ocrevus®], and rituximab [Rituxan®])?

Yes                      No

***If yes, answer question 1a:***

- 1a. For which of the following agents is the evidence adequate to demonstrate that the net health benefit of ublituximab is superior? (Select all that apply.)

- a. Natalizumab
- b. Ofatumumab
- c. Ocrelizumab
- d. Rituximab

2. Given the currently available evidence, is the evidence adequate to demonstrate that the net health benefit of ublituximab is superior to that provided by fumarates (dimethyl fumarate [Tecfidera®], diroximel fumarate [Vumerity®], monomethyl fumarate [Bafiertam®])?

Yes                      No

3. Given the currently available evidence, is the evidence adequate to demonstrate that the net health benefit of ublituximab is superior to that provided by fingolimod (Gilenya®)?

Yes                      No

## Contextual Considerations and Potential Other Benefits or Disadvantages

*Please vote on the following contextual considerations:*

**When making judgments of overall long-term value for money, what is the relative priority that should be given to any effective treatment for multiple sclerosis, on the basis of the following contextual considerations:**

1=Very low priority; 2=Low priority; 3=Average priority; 4=High priority; 5=Very high priority

1. Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability
2. Magnitude of the lifetime impact on individual patients of the condition being treated
3. Other (as relevant)

*Please vote on the following potential other benefits or disadvantages:*

**What are the relative effects of ublituximab versus dimethyl fumarate on the following outcomes that inform judgment of the overall long-term value for money of ublituximab?**

1=Major negative effect; 2=Minor negative effect; 3=No difference; 4=Minor positive effect; 5=Major positive effect

4. Patients' ability to achieve major life goals related to education, work, or family life
5. Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life
6. Society's goal of reducing health inequities
7. Other (as relevant)

## Long-Term Value for Money

8. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with ublituximab versus dimethyl fumarate?
  - a. Low long-term value for money at current price
  - b. Intermediate long-term value for money at current price
  - c. High long-term value for money at current price